Here’s a summary of the WorldHealth.net article “Liver Health and MASH: What You Need to Know About the Silent Epidemic”:
🩺 What is MASH?
- MASH (Metabolic Dysfunction-Associated Steatohepatitis), formerly NASH, is an advanced form of fatty liver disease characterized by fat buildup + inflammation, often progressing silently to fibrosis, cirrhosis, liver failure, or cancer.
🔍 Risk Factors & Trends
- Key risk factors include obesity, type 2 diabetes, high blood pressure, high triglycerides, low HDL cholesterol, and insulin resistance—all fueling liver inflammation and scarring worldhealth.net.
- MASH is increasingly being diagnosed in younger people, including teens and young adults, driven by rising childhood obesity, poor diets, and sedentary lifestyles.
⚠️ Why It’s Called the “Silent Epidemic”
- Early stages are often symptom-free, making timely detection difficult without proactive testing time.news.
- Possible early warning signs: persistent fatigue, upper-right abdominal pain, leg or abdominal swelling, jaundice, or brain fog.
🧪 Diagnosis
- Routine blood tests (e.g., FIB-4 index, liver enzymes), imaging (ultrasound, elastography), and lipid panels are used.
- Liver biopsy remains the gold standard but is invasive; non-invasive methods are preferred for early detection.
🌱 Treatment & Prevention
- First-line: lifestyle changes—weight loss, healthier eating (low sugar/fat), regular exercise, limiting alcohol.
- Medications:
- Resmetirom, FDA-approved in 2024, is the first drug for MASH.
- Other approaches include glucose/lipid-lowering agents and potential weight-loss drugs.
- Global awareness: The article calls for widespread screening, especially in high‑risk individuals, and education campaigns to intercept disease early.
✅ Bottom Line
MASH is a stealthy yet rapidly growing public health threat, affecting people across all ages. Its stealthy progression emphasizes the need for proactive screening, lifestyle intervention, and early use of emerging therapies like resmetirom to prevent long-term liver damage.